VEGF通路胚系多态性预测非晚期分化型甲状腺癌复发
这项多中心回顾性观察研究纳入204例I-II期和240例低-中危分化型甲状腺癌患者,分析VEGF-A与VEGFR-2胚系单核苷酸多态性。联合VEGF-A三个SNP的ACG纯合基因型在I-II期具保护性(OR 0.08,P=0.018),CTG纯合基因型与I-II期复发显著相关(OR 5.47,P=0.018);保护性基因型患者原发肿瘤微血管密度较低(中位76.5±12.7 vs 86.7±27.9,P=0.024)。
要点
- VEGF-A SNP组合的ACG纯合基因型在I-II期患者中与复发风险降低相关(OR 0.08,P=0.018)。
- CTG纯合基因型与I-II期复发风险升高相关(OR 5.47,P=0.018)。
- 保护性基因型患者原发肿瘤微血管密度低于其他基因型(76.5±12.7 vs 86.7±27.9,P=0.024)。
核心结论
- 胚系VEGF-A SNP分析可能有助于分化型甲状腺癌的预后评估。
研究设计与样本
- 多中心、回顾性、观察性研究,纳入连续分化型甲状腺癌患者,采集血样。
- 共纳入204例I-II期患者(平均随访73±64个月)和240例低-中危患者(平均随访70±60个月)。
- 采用TaqMan方案对4个VEGF-A SNP(-2578C>A、-460T>C、+405G>C、+936C>T)和2个VEGFR-2 SNP(+1192C>T、+1719T>A)进行基因分型。
- 通过CD34染色评估微血管密度(MVD)。
主要发现
- 联合VEGF-A SNP -2578 C>A、-460 T>C和+405 G>C识别出两种风险基因型。
- ACG纯合基因型在I-II期患者中具保护性(OR 0.08;95%CI 0.01至1.43;P=0.018),在低-中危患者中OR 0.14(95%CI 0.01至1.13;P=0.035)。
- CTG纯合基因型与I-II期复发显著相关(OR 5.47;95%CI 1.15至26.04;P=0.018),在低-中危患者中OR 3.39(95%CI 0.8至14.33;P=0.079)。
- 保护性基因型患者原发肿瘤中位MVD为76.5±12.7,其他基因型为86.7±27.9,差异有统计学意义(P=0.024)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Tumor angiogenesis is determined by host genetic background rather than environment. Germline single nucleotide polymorphisms (SNPs) of the vascular endothelial growth factor (VEGF) pathway have demonstrated prognostic value in different tumors. OBJECTIVES: Our main objective was to test the prognostic value of germline SNPs of the VEGF pathway in nonadvanced differentiated thyroid cancer (DTC). Secondarily, we sought to correlate analyzed SNPs with microvessel density (MVD). DESIGN: Multicenter, retrospective, observational study. SETTING: Four referral centers. PATIENTS: Blood samples were obtained from consecutive DTC patients. Genotyping was performed according to the TaqMan protocol, including 4 VEGF-A (-2578C>A, -460T>C, +405G>C, and +936C>T) and 2 VEGFR-2 (+1192 C>T and +1719 T>A) SNPs. MVD was estimated by means of CD34 staining. OUTCOME MEASURES: Rate of recurrent structural disease/disease-free survival (DFS). Difference in MVD between tumors from patients with different genotype. RESULTS: Two hundred four patients with stage I-II DTC (mean follow-up, 73 ± 64 months) and 240 patients with low- to intermediate-risk DTC (mean follow-up, 70 ± 60 months) were enrolled. Two "risk" genotypes were identified by combining VEGF-A SNPs -2578 C>A, -460 T>C, and +405 G>C. The ACG homozygous genotype was protective in both stage I-II (odds ratio [OR], 0.08; 95% confidence interval [CI], 0.01 to 1.43; P = 0.018) and low- to intermediate-risk (OR, 0.14; 95% CI, 0.01 to 1.13; P = 0.035) patients. The CTG homozygous genotype was significantly associated with recurrence in stage I-II (OR, 5.47; 95% CI, 1.15 to 26.04; P = 0.018) and was slightly deleterious in low- to intermediate-risk (OR, 3.39; 95% CI, 0.8 to 14.33; P = 0.079) patients. MVD of primary tumors from patients harboring a protective genotype was significantly lower (median MVD, 76.5 ± 12.7 and 86.7 ± 27.9, respectively; P = 0.024). CONCLUSIONS: Analysis of germline VEGF-A SNPs could empower a prognostic approach to DTC.
引用
- Marotta V, Sciammarella C, Capasso M, et al. Germline Polymorphisms of the VEGF Pathway Predict Recurrence in Nonadvanced Differentiated Thyroid Cancer. J Clin Endocrinol Metab. 2017. PMID: 27849428. doi:10.1210/jc.2016-2555
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。